Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Post-authorization Long-term Follow-up Study to Characterize the Effectiveness and Safety of HEMGENIX® (Etranacogene Dezaparvovec) in Patients With Hemophilia B

NCT06008938 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT06008938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06008938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Post-authorization Long-term Follow-up Study to Characterize the Effectiveness and Safety of HEMGENIX® (Etranacogene Dezaparvovec) in Patients With Hemophilia B
Lead sponsor
CSL Behring
Phase
Observational
Overall status
Recruiting
Start date
June 15, 2023
Completion date
August 1, 2043
Enrollment
500 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia b